A new report by the Australian New Zealand Clinical Trial Registry, housed in NHMRC Clinical Trials Centre at the University of Sydney reveals interesting insights into clinical trials in Australia, where more than $1 billion is invested each year by both government and industry.
Published today, the report represents one of the most comprehensive assessments of clinical trial activity in Australia ever undertaken. Drawing on data from 10,549 Australian clinical trials registered between 2006-2015, the report highlights important national trends in Australian clinical trial activity.
“Clinical trials are an essential part of an effective and efficient health care sector, and a vital strategy in ensuring better health for all Australians,” said Associate Professor Lisa Askie, Director of Systematic Reviews and Health Technology Assessment, at the University’s NHMRC Clinical Trials Centre.
“They ensure that the best treatments, to both prevent and treat illness, are assessed rigorously before being implemented into routine care.
“As such, it is vital to ensure that the clinical trials we are doing in Australia meet the needs of our citizens, and that the clinical trials sector remains robust and competitive by international standards.
“By conducting clinical trials in this country we enable Australians to access the best available health care options by capitalising on effective and efficient therapies, reducing research waste and maximising value for money from the health care dollars invested.”
“The information contained within this report will help consumers, clinicians, industry, universities and those in the health care sector to better prioritise, plan and perform clinical trials,” said Professor Askie.
“This will lead to innovation and efficiency, and will help improve the health of all Australians.
“Future investment in clinical trials is likely to continue to produce large health benefits. Prioritisation of trials should be based on factors such as disease burden or gaps in health outcomes between different populations, and include those areas with the potential to have a greater impact and return on investment.
“For example, clinical trials targeting interventions in the perinatal or early childhood period could be important in terms of lifetime benefits.”
Read the full report here.